iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
145.23
+1.40 (0.97%)
At close: Jun 5, 2025, 4:00 PM
145.73
+0.50 (0.34%)
After-hours: Jun 5, 2025, 6:33 PM EDT
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $158.68M in the quarter ending March 31, 2025, with 20.27% growth. This brings the company's revenue in the last twelve months to $618.59M, up 20.54% year-over-year. In the year 2024, iRhythm Technologies had annual revenue of $591.84M with 20.13% growth.
Revenue (ttm)
$618.59M
Revenue Growth
+20.54%
P/S Ratio
7.36
Revenue / Employee
$309,294
Employees
2,000
Market Cap
4.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
| Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
| Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
| Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
| Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IRTC News
- 15 hours ago - iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Reach Out - Accesswire
- 15 days ago - iRhythm Technologies to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts - Benzinga
- 5 weeks ago - iRhythm Technologies, Inc. (IRTC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection - GlobeNewsWire